Coombs Test - Direct

The Coombs Test - Direct, also known as the Direct Antiglobulin Test (DAT), helps diagnose various conditions in which the body’s immune system mistakenly targets and attacks its own red blood cells, leading to their premature destruction (hemolysis). 

Unlike the Indirect Coombs Test, which looks for free-floating antibodies in the blood, the direct version focuses on antibodies already attached to RBCs. This makes it particularly useful in diagnosing autoimmune hemolytic anemia (AIHA), where the immune system mistakenly identifies RBCs as foreign substances and attacks them. These antibodies (also called autoantibodies) can cause the RBCs to break apart, leading to symptoms such as fatigue, jaundice, and anemia.

The Coombs Test - Direct plays a critical role in managing hemolytic disease of the newborn (HDN) by detecting maternal antibodies that might have crossed the placenta, leading to the destruction of the baby’s RBCs. This test also investigates transfusion reactions by detecting antibodies that attack the transfused red blood cells if a patient receives a blood transfusion and the immune system reacts to the donor blood. This test also investigates transfusion reactions by detecting antibodies that attack the transfused red blood cells if a patient’s immune system reacts to the donated blood.

It is also used to assess drug-induced hemolytic anemia, a condition in which certain medications can trigger the immune system to target red blood cells, often resulting in anemia and other symptoms related to hemolysis.

No special preparation is required for this test. Inform the doctor about all the medications or supplements being taken, as these could affect the test results, potentially requiring dosage adjustments or temporary discontinuation before the test. 

Lab test results may vary across laboratories. Interpretation of the test results requires professional expertise. Therefore, do not self-medicate. Always consult the doctor to understand the test results correctly.